Eye Bio is a clinical-stage ophthalmology biotech company focused on developing innovative therapies to protect, restore, and improve vision for patients with eye diseases. The company was co-founded by leaders in the field who previously introduced the first anti-VEGF therapy for age-related macular degeneration. With a strong backing from prominent healthcare investors, Eye Bio is building a diverse pipeline of advanced therapies, including its lead asset Restoret, which targets the Wnt pathway for retinal diseases. The company's experienced leadership and commitment to innovation position it well in the ophthalmology market, aiming to redefine treatment standards for eye diseases.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision-guided therapeutics, particularly for solid tumors. Their unique Bicycle technology allows for targeted delivery of therapies, addressing significant unmet medical needs in oncology and beyond. The company collaborates with various pharmaceutical partners to explore applications in multiple therapeutic areas, including anti-infective and cardiovascular diseases. With a strong pipeline and innovative approach, Bicycle aims to transform patient outcomes and establish itself as a leader in the biopharmaceutical industry.
Septerna is a clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Native Complex Platform™, focusing on developing oral small molecule therapies for endocrinology, immunology, inflammation, and metabolic diseases. The company aims to unlock the potential of difficult-to-drug GPCRs, advancing a deep pipeline of drug candidates to address significant unmet medical needs. With a world-class team of experts, Septerna is positioned to make a substantial impact in the biotechnology sector, leveraging cutting-edge science and collaboration to drive innovation and results.
Sono Thera is a biotechnology company focused on developing an ultrasound-mediated nonviral gene therapy platform aimed at delivering genetic medicines to treat a variety of diseases. Their innovative approach utilizes ultrasound microbubbles for targeted, non-invasive delivery to organs, addressing significant barriers in gene therapy such as safety, efficacy, and cost. With a mission to improve the lives of millions, Sono Thera is positioned to revolutionize the treatment landscape for conditions with limited or no existing therapies, leveraging a technology with an established safety track record and the potential for diverse nucleic acid payloads.
Elevate Bio is a technology-driven cell and gene therapy company that accelerates access to cutting-edge technologies and expertise to transform medicine. Founded in 2017, the company integrates multiple R&D technology platforms, including Life Edit for gene editing, and Base Camp for cGMP manufacturing, to enable the development of a wide range of cell and gene therapies. Elevate Bio partners with industry leaders and academic institutions to streamline the process from research to commercialization, positioning itself as a key player in the rapidly evolving genetic medicines market.
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.
Obsidian Therapeutics is pioneering engineered cell and gene therapies using its proprietary cyto DRi VE® platform to develop precision medicines. The company focuses on creating adoptive immunotherapies, particularly through its lead clinical program OBX-115, which has received FDA designations for advanced melanoma treatment. Their innovative approach allows for controlled protein activity in cells, enhancing the efficacy of cell therapies. With a strong pipeline and collaborations with major partners, Obsidian is positioned to make significant impacts in oncology and improve patient outcomes.
Moximed is a pioneering medical device company focused on enhancing care for patients suffering from osteoarthritis through its innovative MISHA Knee System. This implantable shock absorber (ISA) is designed for patients with medial knee osteoarthritis who have not found relief from other treatments and are not candidates for knee replacement. The MISHA Knee System aims to improve patient outcomes by providing a quick recovery time and clinically meaningful pain relief, positioning Moximed as a leader in the orthopedic market. With strong clinical results and a commitment to patient care, Moximed is well-positioned for growth in the medical device industry.
Earlens is a privately held medical technology company focused on transforming the hearing experience for individuals with hearing loss. The company has developed the Earlens® Contact Hearing Solution, which utilizes a tiny lens to directly vibrate the eardrum, activating the natural hearing process. This innovative, non-surgical solution offers the broadest bandwidth available today and superior sound quality, addressing common complaints associated with traditional hearing aids. Earlens devices are custom-fit for each patient's unique anatomy and hearing needs, incorporating modern features like Bluetooth streaming. The technology received FDA clearance in 2019 for its second generation, positioning Earlens as a leader in the hearing aid market.
Sonoma Biotherapeutics is a clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases. Founded by pioneers in Treg biology and cell therapy, the company employs proprietary platform technologies to create targeted and durable Treg cell therapies aimed at curing these diseases. Their innovative approach is being validated through ongoing clinical trials, positioning them as leaders in the field of immune system restoration.
